On Wednesday, Angie’s List Inc(NASDAQ:ANGI)’s shares dwindled -6.92%, and closed at $5.65, as on April 2, 2015, the Angie’s List declared that its first quarter 2015 financial results will be released on Wednesday, April 22, 2015, before the open of the market. The corporation will host a conference call at 8:30 a.m. ET to talk about the financial results with the investment community. A live audio webcast of the event will be accessible on the Angie’s List Investor Relations website at http://investor.angieslist.com/.
Angie’s List, Inc. operates a local services marketplace and consumer review site in the United States. The corporation provides marketplace to research, shop for, and purchase local services for home, health, and automotive service needs.
Lions Gate Entertainment Corp. (USA) (NYSE:LGF), declined -6.62%, and closed at $31.45, during the last trading session on Wednesday, as Lionsgate declared recently the pricing of an underwritten secondary offering of 10,000,000 shares of its ordinary shares offered by investment funds associated with MHR Fund Administration LLC at a public offering price of $32.00 per share. These investment funds have granted to the underwriter a 30-day option to purchase up to an additional 1,500,000 ordinary shares. Lionsgate will not sell any shares in the offering and will not receive any proceeds from the offering. The offering is predictable to close on or about April 13, 2015, subject to customary closing conditions.,
Lions Gate Entertainment Corp., an entertainment corporation, is engaged in motion picture production and distribution, television programming and syndication, home entertainment, family entertainment, digital distribution, new channel platforms, and international distribution and sales activities.
At the end of Wednesday’s trade, Prothena Corporation PLC (NASDAQ:PRTA), dipped -6.39%, and closed at $35.16, as a late-stage clinical biotechnology corporation, declared that it priced an underwritten public offering of 3,300,000 of its ordinary shares at a price to the public of $37.00 per ordinary share, before the underwriting discount. All of the ordinary shares in the offering were sold by Prothena. In addition, Prothena has granted the underwriters a 30-day option to purchase up to an additional 495,000 of its ordinary shares.
Net proceeds to Prothena from the ordinary shares to be sold by Prothena in the offering are predictable to be $114.2 million, after deducting the underwriting discount and estimated offering expenses, but not including any exercise of the underwriters` option to purchase additional ordinary shares. The offering is predictable to close on April 13, 2015, subject to customary closing conditions.
Prothena Corporation plc, a late-stage clinical biotechnology corporation, focuses on the discovery, development, and commercialization of protein immunotherapy programs for the treatment of diseases that involve amyloid or cell adhesion in Ireland.
Royal Dutch Shell plc (ADR) (NYSE:RDS.B), ended its Wednesday’s trading session with -6.13% loss, and closed at $61.45, as The Boards of Shell and BG reveal that they have reached contract on the terms of a recommended cash and share offer to be made by Shell for the entire issued and to be issued share capital of BG. Under the terms of the Combination, BG Shareholders will be entitled to receive:
For each BG Share: 383 pence in cash; and
0.4454 Shell B Shares [1]
Based on the 90 trading day volume weighted average price of 2,170.3 pence per Shell B Share on 7 April 2015 (being the last Business Day before the date of this Declarement), the terms of the Combination represent:
a value of about 1,350 pence per BG Share; and
a premium of about 52% to the 90 trading day volume weighted average price of 890.4 pence per BG Share on 7 April 2015.
Royal Dutch Shell plc operates as an independent oil and gas corporation worldwide. It operates through Upstream and Downstream segments. The corporation explores for and extracts crude oil, natural gas, and natural gas liquids.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
